Use of polymethoxylated flavones for treating insulin resistance
First Claim
Patent Images
1. A pharmaceutical composition for treating a mammal having metabolic abnormalities resulting from insulin resistance comprising an effective amount of at least one polymethoxyflavone compound and a suitable pharmaceutically acceptable diluent, carrier or adjuvant.
1 Assignment
0 Petitions
Accused Products
Abstract
Compositions and methods for treating metabolic abnormalities arising from insulin resistance comprises the administration of trangeretin or a mixture of various polymethoxylated flavones (PMF'"'"'s) are described. The PMF'"'"'s are administered in various manners including orally. Supplementation with PMF'"'"'s to individuals affected by insulin resistance syndrome results in normalization of metabolic activity and improved glucose metabolism.
30 Citations
23 Claims
- 1. A pharmaceutical composition for treating a mammal having metabolic abnormalities resulting from insulin resistance comprising an effective amount of at least one polymethoxyflavone compound and a suitable pharmaceutically acceptable diluent, carrier or adjuvant.
- 8. The use of a metabolic abnormality reducing amount of at least one polymethoxyflavone in a mammal experiencing insulin resistance syndrome.
- 15. A method of treating a mammal having metabolic abnormalities resulting from insulin resistance comprising administering an effective amount of at least one polymethoxyflavone compound.
-
17. The method of 15 wherein said polymethoxyflavone is tangeretin.
Specification